McMahon 2022.
Study characteristics | |
Methods | Randomized placebo‐controlled trial |
Participants | PCR‐confirmed COVID‐19 |
Interventions | Favipiravir, placebo |
Outcomes | The primary endpoint was time to virological cure, defined as 2 successive swabs negative for SARS‐CoV‐2 by PCR. Secondary outcomes were progression of disease severity, symptom resolution, and safety. |
Notes |